Oncology-focused molecular diagnostics company Pathwork Diagnostics (Sunnyvale, Calif.) has closed on a $20 million funding round led by Abingworth, a venture capital firm that specializes in early-stage life sciences and biomedical companies. Other investors included Prospect Venture Partners and Advent Venture Partners. This is Pathwork’s second funding round.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2008 - Table of Contents

DTTR October 2008 (full PDF issue)

Myriad Genetics May Spin Off Pharma Business

FDA Clears Third IVDMIA: XDx’s AlloMap

Nanogen to Merge With French Diagnostics Company

Meridian Bioscience Inks Canadian Distribution Deal

Inside the Diagnostics Industry: Nanogen’s David Ludvigson on Mergers, Markets, and Microarrays

New Gene Variant Linked to Prostate Cancer Risk

Protein Variant Predicts Chemotherapy Response

Pathwork Diagnostics Raises $20 Million

Pall Corporation Acquires GeneSystems

Physicians Frustrated by CMS’s Quality Reporting Initiative Feedback

IVD Stocks Down 6%; OraSure, Luminex Only Gainers

Biomarker for Soft Tissue Sarcoma